Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Carlen A Yuen"'
Publikováno v:
CNS Oncology, Vol 13, Iss 1 (2024)
Glioblastoma is the most common malignant primary brain tumor. Despite its infiltrative nature, extra-cranial glioblastoma metastases are rare. We present a case of a 63-year-old woman with metastatic glioblastoma in the lungs. Sarcomatous histology,
Externí odkaz:
https://doaj.org/article/925db50d702243e1a7e495190f96a876
Autor:
Carlen A. Yuen, Silin Bao, Xiao-Tang Kong, Merryl Terry, Alexander Himstead, Michelle Zheng, Melike Pekmezci
Publikováno v:
Biomedicines, Vol 12, Iss 9, p 2042 (2024)
The World Health Organization’s (WHO) classification of central nervous system (CNS) tumors is continually being refined to improve the existing diagnostic criteria for high-grade gliomas (HGGs), including glioblastoma. In 2021, advances in molecul
Externí odkaz:
https://doaj.org/article/4618db11b5c64bfc9565060af5066242
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
It is an unmet need to estimate survival duration for patients with progressive supranuclear palsy (PSP). The objective of this study was to identify factors associated with the survival duration in patients with PSP. We followed up 23 patients with
Externí odkaz:
https://doaj.org/article/5d4a0f19cbb7492bb42161499ab16125
Autor:
Carlen A, Yuen, Jing-Mei, Hsu, Koen, Van Besien, Ran, Reshef, Fabio M, Iwamoto, Aya, Haggiagi, Benjamin, Liechty, Cenai, Zhang, Sarah F, Wesley, Rajiv, Magge
Publikováno v:
Journal of Immunotherapy. 45:254-262
Secondary central nervous system lymphoma (SCNSL) is associated with poor prognosis and new therapeutic approaches are needed. The pivotal trial that led to US Food and Drug Administration (FDA) approval of axicabtagene ciloleucel excluded patients w
Publikováno v:
Current Oncology Reports
Purpose of Review Elderly patients with newly diagnosed glioblastoma (eGBM) carry a worse prognosis compared with their younger counterparts. eGBM garners special attention due to the unique challenges, including increased treatment-associated toxici
Publikováno v:
Global Perspectives in Ocular Oncology ISBN: 9783031082498
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4eca20689e1e0b9d7450361112e8b3e4
https://doi.org/10.1007/978-3-031-08250-4_9
https://doi.org/10.1007/978-3-031-08250-4_9
Publikováno v:
Current Oncology Reports. 24:387-387
Prior targeted treatment for glioblastoma multiforme (GBM) with anti-angiogenic agents, such as bevacizumab, has been met with limited success potentially owing to GBM tumor's ability to develop a hypoxia-induced escape mechanism – a glycolytic swi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be0f9072aa2517383012704ed1f9b9be
https://europepmc.org/articles/PMC6047435/
https://europepmc.org/articles/PMC6047435/
Publikováno v:
Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology. 28(2)
OBJECTIVE To report our use of persuasion to treat patients with functional vision loss and to place them in the context of both Joseph Babinski's theories on hysteria and the current literature on management of functional vision loss. BACKGROUND Con
Publikováno v:
Clinical Ophthalmology (Auckland, N.Z.)
Transient vision loss may indicate underlying vascular disease, including carotid occlusion and thromboembolism, or it may have a more benign etiology, such as migraine or vasospasm. This review focuses on the differential diagnosis and workup of pat